Skip to main content

Advertisement

SpringerLink
Log in

Clinical Relevance of microRNA Expressions in Breast Cancer Validated Using the Cancer Genome Atlas (TCGA)

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

MicroRNAs (miRNAs) play a critical role in the carcinogenesis and progression of breast cancer. MiRNA-205 has tumor suppressive properties, whereas miRNA-18a has both oncogenic and tumor suppressive roles. MiRNA-744’s role in breast cancer is unknown but is tumor-suppressive in vitro. We hypothesize that high expression of all three miRNAs is associated with a better survival based on their known functions in breast cancer.

Methods

All data was obtained from the Cancer Genome Atlas (TCGA). Expression patterns of miRNA-18a, miRNA-205, and miRNA-744 were retrieved from the Genomic Data Commons (GDC) data portal for analyses. After miRNA-specific thresholds were derived and used to group the patients into a high- or low-expression group, survival data was calculated by using the Cox proportional hazard model. Further subanalyses separating the patients based on receptor status and AJCC 7th edition TNM staging were similarly compared.

Results

In total, 1,052 of 1,097 samples logged in TCGA had clinical data and miRNA-sequence datasets on the miRNAs of interest. High expression of miRNA-18a (p = 0.079), miRNA-205 (p = 0.034), and miRNA-744 (p = 0.0135) was associated with better survival. On subanalysis, estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, and lymph node-negative disease had a statistically significant survival advantage with miRNA-18a, miRNA-205, and miRNA-744 high expression.

Conclusions

By utilizing a big dataset (TCGA) with sufficient statistical power, we found that high expression of miRNA-18a, miRNA-205, and miRNA-744 in the breast tumor samples were all associated with better overall survival in ER/PR-positive, lymph node-negative disease supporting their role as a tumor suppressor in breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Piletic K, Kunej T. MicroRNA epigenetic signatures in human disease. Arch Toxicol. 2016;90(10):2405–19.

    Article  CAS  PubMed  Google Scholar 

  2. Bertoli G, Cava C, Castiglioni I. MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 2015;5(10):1122–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Guo X, Yang C, Qian X, et al. Estrogen receptor alpha regulates ATM Expression through miRNAs in breast cancer. Clin Cancer Res. 2013;19(18):4994–02.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yoshimoto N, Toyama T, Takahashi S, et al. Distinct expressions of microRNAs that directly target estrogen receptor alpha in human breast cancer. Breast Cancer Res Treat. 2011;130(1):331–49.

    Article  CAS  PubMed  Google Scholar 

  5. Krutilina R, Sun W, Sethuraman A, et al. MicroRNA-18a inhibits hypoxia-inducible factor 1alpha activity and lung metastasis in basal breast cancers. Breast Cancer Res. 2014;16(4):R78.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Mouw JK, Yui Y, Damiano L, et al. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat Med. 2014;20(4):360–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009;19(4):439–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lee JY, Park MK, Park JH, et al. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene. 2014;33(10):1325–35.

    Article  CAS  PubMed  Google Scholar 

  9. Gandellini P, Folini M, Longoni N, et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009;69(6):2287–95.

    Article  CAS  PubMed  Google Scholar 

  10. Zhang G, Hou X, Li Y, Zhao M. MiR-205 inhibits cell apoptosis by targeting phosphatase and tensin homolog deleted on chromosome ten in endometrial cancer Ishikawa cells. BMC Cancer. 2014;14:440.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Vislovukh A, Kratassiouk G, Porto E, et al. Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744. Br J Cancer. 2013;108(11):2304–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chen XF, Liu Y. MicroRNA-744 inhibited cervical cancer growth and progression through apoptosis induction by regulating Bcl-2. Biomed Pharmacother. 2016;81:379–87.

    Article  CAS  PubMed  Google Scholar 

  13. Zhou W, Li Y, Gou S, et al. MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/beta-catenin pathway. Oncotarget. 2015;6(35):37557–69.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med. 2011;17(3):297–03.

    Article  CAS  PubMed  Google Scholar 

  15. Ramanathan R, Olex AL, Dozmorov M, Bear HD, Fernandez LJ, Takabe K. Angiopoietin pathway gene expression associated with poor breast cancer survival. Breast Cancer Res Treat. 2017;162(1):191–98.

    Article  CAS  PubMed  Google Scholar 

  16. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.

    Article  Google Scholar 

  17. Weinstein JN, Collisson EA, Mills GB, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113–20.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemporary Oncol. 2015;19(1a):A68–A77.

    Google Scholar 

  19. Liu WH, Yeh SH, Lu CC, et al. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology. 2009;136(2):683–93.

    Article  CAS  PubMed  Google Scholar 

  20. Shidfar A, Costa FF, Scholtens D, et al. (2017) Expression of miR-18a and miR-210 in Normal Breast Tissue as Candidate Biomarkers of Breast Cancer Risk. Cancer Prevention Research 10(1):89–97.

    Article  CAS  PubMed  Google Scholar 

  21. Tsuchida J, Nagahashi M, Rashid OM, Takabe K, Wakai T. At what age should screening mammography be recommended for Asian women? Cancer Med. 2015;4(7):1136–44.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biol. 2008;10(5):59301.

    Article  CAS  PubMed  Google Scholar 

  23. Miyamae M, Komatsu S, Ichikawa D, et al. Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer. Br J Cancer. 2015;113(10):1467–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. TCGA Data Portal. Available at: https://tcga-data.nci.nih.gov/docs/publications/tcga/? Accessed 5 June 2017.

Download references

Disclosure

All authors declare that they have no financial relationships or conflicts of interest.

Author information

Authors and Affiliations

  1. Breast Surgery, Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA

    Sara Y. Kim MD, Tsutomu Kawaguchi MD, PhD, Jessica Young MD & Kazuaki Takabe MD, PhD, FACS

  2. Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA

    Li Yan PhD & Qianya Qi

  3. Department of Surgery, University of Buffalo Jacobs School of Medicine and Biomedical Sciences, The State University of New York, Buffalo, NY, USA

    Kazuaki Takabe MD, PhD, FACS

Authors
  1. Sara Y. Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsutomu Kawaguchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Yan PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jessica Young MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qianya Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuaki Takabe MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuaki Takabe MD, PhD, FACS.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, S.Y., Kawaguchi, T., Yan, L. et al. Clinical Relevance of microRNA Expressions in Breast Cancer Validated Using the Cancer Genome Atlas (TCGA). Ann Surg Oncol 24, 2943–2949 (2017). https://doi.org/10.1245/s10434-017-5984-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-017-5984-2

Keywords

Search

Navigation